Key result
Left atrial appendage occlusion in high-risk NVAF patients contraindicated for OACs achieved 96.4% procedural success, with a 2.2% annual rate of ischaemic stroke over a mean 30-month follow-up.
Why the study?
Does percutaneous left atrial appendage occlusion safely prevent stroke and thromboembolism in high-risk patients with non-valvular atrial fibrillation who have contraindications to oral anticoagulants?
Cohort (n=110)
Does percutaneous left atrial appendage occlusion safely prevent stroke and thromboembolism in high-risk patients with non-valvular atrial fibrillation who have contraindications to oral anticoagulants?
LAA occlusion is a feasible and safe alternative for stroke prevention in high-risk NVAF patients who are contraindicated for oral anticoagulation.
No takes yet. Share an insight, caveat, or question.
Supports LAAO feasibility in OAC-contraindicated high-risk NVAF; leaves open need for RCTs to confirm stroke prevention benefit.
Berti et al. (2016) conducted a cohort in Non-valvular atrial fibrillation (NVAF) with contraindications to oral anticoagulants (n=110). Left atrial appendage (LAA) occlusion (Amplatzer Cardiac Plug or Amulet) was evaluated on Procedural success (technical success without major procedure-related complications). Left atrial appendage occlusion in high-risk NVAF patients contraindicated for OACs achieved 96.4% procedural success, with a 2.2% annual rate of ischaemic stroke over a mean 30-month follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: